HeyJaredDrugPatentWatch – Pharmaceutical and Biotechnology Business Intelligence
DrugPatentWatch serves leading companies ranging from biopharmaceutical R&D to healthcare delivery, and has been cited by CNN, NEJM, Nature Journals, and many other leading publications.Use cases for the DrugPatentWatch platform include:- Branded pharmaceutical global…
- Indexed episodes, last 90 days
- 50
- Latest publication
- Sep 8, 2026
- Audience
- Checking…
- Earliest in this view
- Sep 5, 2026
Latest episodes
Vertex Pharmaceuticals Incorporated v. Squires (opens the original)
Read excerpt
Vertex vs. Squires: The Quiet Legal Battle Behind High-Stakes Drug Pricing Everyone talks about drug pricing like it’s a spreadsheet problem—manufacturers, competitors, and government reimbursement rules. But the reality is that pricing is often decided long before the public sees a price tag, in courtrooms where legal arguments about patents and timing determine who can sell what, and when. That’s what makes the latest development in Vertex Pharmaceuticals, Inc. v. Squires worth attention—not j
The Authorized Generic That Beats the Patent Cliff to Market (opens the original)
Read excerpt
A lot of people talk about the “patent cliff” like it’s a single moment in time—a countdown clock where revenues disappear overnight. But the real story is that the cliff is often beaten , not by breaking the rules, but by exploiting the fine print of the system. That’s the uncomfortable lesson behind the authorized generic strategy highlighted in a recent Drug Patent Watch post: the authorized generic that can hit the market right as the patent expires—effectively sprinting past the anticipated
The Blockbuster’s Real Patent Is the Weak One Nobody Challenged (opens the original)
Read excerpt
Drug Patents Aren’t “Won” in Court—They’re Won in the Quiet Years Before Anyone Notices In pharma, the blockbuster narrative usually goes like this: a company earns exclusivity, a rival challenges, a judge decides, and the market redraws the map. That’s the headline version. But the deeper story is less cinematic—and far more consequential: the most important patent is often the one no one challenges. That’s the central argument in a recent piece from DrugPatentWatch, and it lands with unusual f
The Prior Art Edge: Why Search Quality Beats Legal Firepower in Drug Patent Litigation (opens the original)
Read excerpt
In drug patent litigation, there’s a temptation to treat discovery like a brawl—bigger budgets, faster fights, louder teams. But the most decisive advantage often looks less like “legal firepower” and more like an invisible edge: superior prior art search quality. This is the core message behind the latest post from DrugPatentWatch— “The prior art edge: Why search quality beats legal firepower in drug patent litigation.” And it’s a lesson that’s resonating far beyond IP counsel. The real battlef
No AI Has Ever Been Named Inventor on a Drug Patent. Here’s the Rule That Guarantees It. (opens the original)
Read excerpt
No AI has ever been named an inventor on a drug patent. That’s not a surprise—it’s the rule. For years, the AI industry has asked a deceptively simple question: Can an algorithm be an inventor? The excitement has been understandable—models can generate hypotheses, draft molecules, propose synthetic routes, and comb through massive patent and literature landscapes in seconds. But in the world of drug patents, excitement doesn’t rewrite statutory language. A key Bloomberg-style takeaway from the l
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.
See coverage about DrugPatentWatch – Pharmaceutical and Biotechnology Business Intelligence